Lloyd Minor
Known title: DirectorCIK: 0002038687
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Transaction History
| CAI | ▲ Buy | Grant | 13,192 | $0 | 8/14/2026 | View on chart |
| BIIB | ▼ Sell | Open Market | 593 | $119K | 8/4/2026 | View on chart |
| BIIB | ▼ Sell | Open Market | 593 | $121K | 8/3/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 1,505 | $0 | 6/9/2026 | View on chart |
| CAI | ▲ Buy | Grant | 2,492 | $50K | 2/26/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 2,370 | $0 | 6/17/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
CAI Trades Amid Market Rally Following Google's Nuclear Deal
The S&P 500 and Nasdaq reached record highs, with power stocks rallying after news of Google's nuclear deal. The broader market rally could lift many stocks, including CAI, which trades near its 52‑week low. CAI remains in a neutral technical zone with an RSI near 50 and support at $15.28.
CAI Trades Amid Market Rally Following Google's Nuclear Deal. The S&P 500 and Nasdaq reached record highs, with power stocks rallying after news of Google's nuclear deal. The broader market rally could lift many stocks, including CAI, which trades near its 52‑week low. CAI remains in a neutral technical zone with an RSI near 50 and support at $15.28.